ASH Review VIRTUAL 2020: Current Updates in Hematologic Diseases

 

ASH Review VIRTUAL 2020: Current Updates in Hematologic Diseases
K

1L Therapy for T-ALL: What Are the AALL0434 vs. AALL1231 EFS/OS Outcomes? Is There More Gr4-5 Infectious Toxicity in AALL1231?

By ASH Review VIRTUAL 2020: Current Updates in Hematologic Diseases FEATURING Ken Byrd
By ASH Review VIRTUAL 2020: Current Updates in Hematologic Diseases FEATURING Ken Byrd
85 views
March 5, 2021
Comments 0
Login to view comments. Click here to Login

Featured Video

16:26
Incyte

Effects of a Treatment Option on Hematocrit Control and Spleen Volum…

Feat. C. Harrison

Featured Video

15:43
Incyte

Importance of Early Management of Patients with Myelofibrosis (MF)

Feat. P. Bose, R. Rampal
Videos
17:35

COVID-19 Coagulopathy: What Is Virchow’s Triad? What Are the VTE Rat…

ASH Review VIRTUAL 2020: Current Updates in Hematologic Diseases

P. Harris

16 views
18:31

COVID-19 Therapeutics: Remdesivir/Bamlanivimab/Casirivimab+Imdevimab…

ASH Review VIRTUAL 2020: Current Updates in Hematologic Diseases

K. Konrardy

11 views
15:40

COVID-19 & Hematologic Malignancies: What Is the Mortality Estimate …

ASH Review VIRTUAL 2020: Current Updates in Hematologic Diseases

J. Leal

23 views
19:48

2021 Updates on Thrombosis: VTE & Recurrence, Use of DOACs in GI/GU …

ASH Review VIRTUAL 2020: Current Updates in Hematologic Diseases

K. Halkidis

26 views
17:38

CAR-T & Experimental Therapeutics for AML: Is Allo-SCT the Only Chan…

ASH Review VIRTUAL 2020: Current Updates in Hematologic Diseases

T. Lin

17 views
15:46

SCT for MDS: Do Older Patients With Advanced MDS Benefit From Allo-H…

ASH Review VIRTUAL 2020: Current Updates in Hematologic Diseases

A. Singh

118 views
05:21

HCT in MF: Is OS Better With Upfront JAKi vs. HCT? What Are the Outc…

ASH Review VIRTUAL 2020: Current Updates in Hematologic Diseases

A. Singh

83 views
09:23

ASH Update on HCT for AML: Are We Starting to Refer AML Patients Ear…

ASH Review VIRTUAL 2020: Current Updates in Hematologic Diseases

M. Mushtaq

49 views
07:01

Allogeneic Transplantation & AML Outcomes: What Is the Role of HSCT …

ASH Review VIRTUAL 2020: Current Updates in Hematologic Diseases

M. Mushtaq

12 views
08:38

ASH Update on Myelofibrosis: What Are the Outcomes After Ruxolitinib…

ASH Review VIRTUAL 2020: Current Updates in Hematologic Diseases

A. Yacoub

125 views
07:44

ASH Update on CML Management: Does the TKI Choice Affect Survival? A…

ASH Review VIRTUAL 2020: Current Updates in Hematologic Diseases

A. Yacoub

92 views
09:26

1L Therapy for Ph- B-ALL: What Is Blinatumomab MRD Response & RFS? I…

ASH Review VIRTUAL 2020: Current Updates in Hematologic Diseases

K. Byrd

20 views
09:20

1L Therapy for T-ALL: What Are the AALL0434 vs. AALL1231 EFS/OS Outc…

ASH Review VIRTUAL 2020: Current Updates in Hematologic Diseases

K. Byrd

85 views
06:36

ASH Update on Intensive Induction for AML: What Is the 5-Year Follow…

ASH Review VIRTUAL 2020: Current Updates in Hematologic Diseases

H. Male

151 views
11:45

ASH Update on Moderate-Intensity Chemo for AML: What Are the Remissi…

ASH Review VIRTUAL 2020: Current Updates in Hematologic Diseases

H. Male

12 views
11:54

ASH Update on MDS Management: What Are the Outcomes of Venetoclax fo…

ASH Review VIRTUAL 2020: Current Updates in Hematologic Diseases

B. Skikne

166 views
08:01

TP53 Mutations in MDS: Is Combination of Eprenetapopt + AZA Well-Tol…

ASH Review VIRTUAL 2020: Current Updates in Hematologic Diseases

B. Skikne

119 views
14:31

ASH Update on Higher-Risk MDS: Efficacy/Safety of Pevonedistat + Aza…

ASH Review VIRTUAL 2020: Current Updates in Hematologic Diseases

B. Skikne

119 views